anti- CALCRL antibody

Background

Calcitonin Receptor-Like Receptor (CALCRL) is a member of the G-protein-coupled receptor (GPCR) family and plays a critical role in diverse physiological processes by interacting with Receptor Activity Modifying Proteins (RAMPs). Its function depends on the specific RAMP partner, leading to the formation of multiple receptor subtypes with distinct biological roles. When CALCRL associates with RAMP1, it forms the Calcitonin Gene-Related Peptide (CGRP) receptor, which regulates vasodilation, pain transmission, and neurogenic inflammation, especially in migraine pathophysiology. Conversely, when paired with RAMP2 or RAMP3, CALCRL becomes a receptor for adrenomedullin (AM) and adrenomedullin 2/intermedin, respectively. These signaling pathways are vital for maintaining vascular tone, endothelial barrier integrity, and angiogenesis, especially during conditions like sepsis, heart failure, and ischemic injuries. CALCRL expression is prominent in the cardiovascular system, kidneys, lungs, and central nervous system, making it a critical target for therapeutic interventions in vascular diseases and inflammatory conditions. Dysregulation of CALCRL is implicated in pathological states, such as pulmonary hypertension, cardiac hypertrophy, and cancer progression, where it promotes tumor angiogenesis and metastasis. Given its widespread biological importance, CALCRL is being actively studied as a therapeutic target, with antagonists and modulators showing promise for treating migraines, hypertension, and cardiovascular disorders. Additionally, its role in fluid regulation and immune responses highlights its systemic relevance across various organs.